PRA Announces Strategic Relationship with Amgen
Biosimilar Development Program
RALEIGH, N.C., April 26, 2012 /PRNewswire via COMTEX/ -- PRA, a leading Clinical
Research Organization, announces a new agreement with Amgen for a series of Phase
III studies to develop several biosimilar drugs on a worldwide basis. It is
intended that PRA will serve as the sole provider of CRO services for these
studies. A global leader in the biotechnology space, Amgen conducted a thorough
search process to identify a CRO for Amgen's biosimilar development program and
selected PRA. Amgen and PRA signed the agreement in April 2012.
Under the new agreement, Amgen and PRA will work together to execute Phase III
studies related to Amgen's current biosimilar portfolio. The agreement is
intended to govern the entire anticipated scope of Amgen's global biosimilar
portfolio.
"This agreement reflects and confirms PRA's commitment to providing full service
support to our clients' development pipelines," said Kent Thoelke, PRA's
Executive Vice President of Scientific and Medical Affairs. "Our mission is to
assist our clients across all phases of biotech drug development by combining
therapeutic and operational expertise with local knowledge to help them meet
their development goals. As such, this relationship represents a key milestone in
PRA's commitment to supporting our clients' biosimilar development programs.
Amgen is a blue chip company and a world leader with a global reputation for
excellence in bringing biologic therapies to patients with grievous illnesses.
PRA has a strong track record in executing our clients' global registration
trials and helping to bring new drugs to market. We are delighted to announce
this strategic relationship with Amgen."
About PRA PRA is transforming clinical trials through our people, innovation and
transparency. PRA provides personalized service customized to the unique
requirements of each study. We support our global reach and innovative approach
through flexible and reliable service, delivered by skilled employees dedicated
to ensuring that sponsors achieve their long-term goals.
We serve our clients across all phases of pharmaceutical and biotech drug
development by combining therapeutic and operational expertise with local
knowledge. Offering services in 80+ countries and serving sponsors for 30+ years,
we have amassed a level of expertise that has enabled us to work on a variety of
compounds, ranging from niche treatments and therapies to blockbuster drugs. But
at PRA, we are looking to the future, not the past. Our increasingly
forward-thinking approach to transforming the clinical trial landscape will
continue to make a difference to healthcare patients around the world.
To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or
call our Global Headquarters.
SOURCE PRA
Copyright (C) 2012 PR Newswire. All rights reserved
